India's Coffee Exports More Than Double In Last 11 Years
New Delhi: India's coffee exports have more than doubled to $1.8 billion in the last 11 years, with the country becoming the 5th largest exporter, according to the government data. India's coffee exports stood at $800 million in 2014-15 and have been rising steadily since then.
The top export markets for Indian coffee are Italy, Germany, Russia, Belgium, the United Arab Emirates (UAE) and the US. India is the seventh largest producer and the fifth largest exporter of coffee in the world. Prices of coffee are ruling at record levels following an adverse weather-induced supply crunch in the largest producing countries of Brazil and Vietnam. India exports over two-thirds of the over 3.5 lakh tonnes produced in the country.
The country's coffee exports have grown significantly due to the increasing global demand for its rich and unique flavours. Approximately three-fourths of India's coffee production consists of Arabica and Robusta beans. These are primarily exported as unroasted beans. However, there is a growing demand for value-added products like roasted and instant coffee, further fuelling the export boom.
India's coffee is primarily grown in the ecologically rich Western and Eastern Ghats, areas famous for their biodiversity. Karnataka leads in production, contributing 248,020 MT in 2022-23, followed by Kerala and Tamil Nadu. These areas are home to shaded plantations that not only support the coffee industry but also play a vital role in preserving the natural environment, helping to maintain the ecological balance of these biodiversity hotspots.
Meanwhile, due to the rise of the cafe culture, higher disposable incomes and a growing preference for coffee over tea, coffee consumption in India is also steadily increasing. This trend has been observed particularly in both urban and rural areas. Domestic consumption has increased from 84,000 tonnes in 2012 to 91,000 tonnes in 2023.
To enhance coffee production and meet growing domestic and international demand, the Coffee Board of India has launched several important initiatives. Through the Integrated Coffee Development Project (ICDP), the focus is on improving yields, expanding cultivation in non-traditional regions and ensuring the sustainability of coffee farming. These measures are part of a comprehensive strategy to strengthen India's coffee industry, increase productivity and improve its global competitiveness.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
43 minutes ago
- Hindustan Times
Housing sales decline 20% in India, 25% in MMR
Mumbai: Increasing property prices and geopolitical tensions across the world have hit housing sales in seven metropolitan cities in India, with sales dropping by 20% in the second quarter of 2025 compared to the second quarter of 2024. The Mumbai Metropolitan Region (MMR) was hit the hardest, with housing sales dropping by 25%, from 41,540 units in the second quarter of 2024 to 31,275 units in the second quarter of 2025, according to a report by real estate consulting firm, Anarock. (Hindustan Times) Approximately 96,285 houses were sold in the second quarter (April-June) of 2025 across the seven metropolitan cities – National Capital Region, MMR, Bengaluru, Pune, Hyderabad, Chennai and Kolkata, compared to 120,335 houses sold in the same period in 2024. Housing sales in the seven cities increased marginally by 3% compared to the first quarter of 2025, the report shows. Chennai, the National Capital Region (NCR), Hyderabad and Bengaluru witnessed a spike in sales by 40%, 14%, 9% and 1% respectively. But in Kolkata, Pune and the MMR, housing sales dropped by 10%, 4% and 1%, respectively. 'The second quarter of 2025 was a rollercoaster for the Indian housing market, rocked by major military actions at home and abroad. The war-like climate pushed homebuyers into wait and watch mode, compounding the impact of soaring property prices over the past two years,' Anuj Puri, chairman, Anarock Group, told Hindustan Times. 'Now, with domestic tensions easing and the Reserve Bank of India's repo rate cut injecting fresh optimism, buyer sentiment is rebounding.' Similar sentiments were shared by other real estate consultants. 'Geopolitical tensions always have an impact on Indian real estate, though the degree varies depending on the geography and Indian economic interests in those countries,' said a real estate consultant, requesting anonymity. 'This time around, with America intervening in the Iran-Israel war, people feared that a medium to large-scale conflict may lead to economic slowdown or job cuts. Hence, home hunters decided to keep their purchase decisions on hold.' In keeping with the dip in sales, new launches decelerated by 16% on a year-on-year basis, from approximately 117,165 units in the second quarter of 2024 to around 98,625 units in the second quarter of 2025. Realty hotspots MMR and NCR saw the maximum new supply, accounting for 48% of the total new supply across the seven cities. MMR witnessed a 36% yearly decline and a 8% quarterly decline in new supply. One of the top developers in the MMR, who recently launched a project in the extended Navi Mumbai area, said, 'When the Ukraine-Russia conflict broke out in February 2022, we thought it would last only a few weeks, but we have been proved wrong. But that conflict did not have as much impact on India's realty industry as the one in the Middle East, especially with America's involvement.' Puri was optimistic about an uptick in sales in forthcoming quarters. 'Despite a 20% year-on-year dip in sales across the top seven cities, a 3% uptick this quarter signals renewed momentum,' he said. 'With home loan rates softening and developers largely holding prices steady, the stage is set for a potential upswing in housing sales in the coming quarters.'
Time of India
an hour ago
- Time of India
Torrent Pharma to acquire JB Chemicals at Rs 25,689 crore valuation
Torrent Pharma will acquire a controlling stake in JB Chemicals from KKR. The deal values JB Chemicals at Rs 25,689 crore. This merger will elevate Torrent to fifth position in the Indian pharmaceutical market. KKR is expected to gain a fivefold return on its 2020 investment. The combined entity aims for significant revenue and profitability growth. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Ahmedabad-based drugmaker Torrent Pharma has agreed to buy a controlling stake in JB Chemicals from global private equity firm KKR at an equity valuation of Rs 25,689 crore ($3 billion). The deal, which will see a merger of the two entities, is among the biggest in the Indian pharmaceutical sector and brings to an end year-long negotiations. They had come close to a deal last year but couldn't agree on valuation at the the acquisition of JB Chemicals, Torrent will move up to fifth rank by market share in the $26 billion Indian pharmaceutical market ahead of Alkem and Intas Pharma. ET had on June 29 been the first to report on the merger deal was announced following a marathon meeting of Torrent Pharma's board of directors on against the stock's Friday close of Rs 1,792. Torrent will also acquire up to 2.8% equity from certain employees of JB Chemicals at the Rs 1,600 apiece. The second part of the deal will follow amerger between Torrent and JB Chemicals through a scheme of arrangement. As per the approval by the two boards, upon the merger, every shareholder holding 100 shares in JB Chemicals will get 51 shares of Torrent. KKR had been the first to seek a restart of negotiations, according to the people cited above. Even at the discounted price, it will end with a fivefold return on what it paid to acquire JB Chemicals in Pharma posted FY25 revenue of Rs 11,500 crore, of which the Indian market accounted for Rs 6,393 crore. JB Chemicals recorded total FY25 sales of Rs 3,918 crore, of which the Indian market accounted for Rs 2,269 crore, growing at 20% over the previous the last decade, Torrent has grown inorganically with a string of deals that included skincare drugs maker Curatio in 2022 and more recently a range of anti-diabetes drugs from Boehringer Ingelheim. Apress statement from Torrent Pharma said the transaction marks a significant step in its ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO (contract development and manufacturing) capabilities. The deal is a strong fit for Torrent and complements its India presence, helping it move into the promising field of contract manufacturing besides allowing for market synergy, an analyst said. 'Torrent has a proven record of making deals work successfully,' the person company will get access to leading brands in the chronic segment and entry into untapped therapeutic areas such as ophthalmology. Torrent said it will derive operational synergies across multiple business functions. 'We are pleased to have on board the JB Chemicals heritage and build on the platform for the future,' said Torrent Pharma executive chairman Samir Mehta. 'Torrent's deep India presence and JB Chemicals' fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability.'For KKR, this follows strong investment activity in India, where the buyout group has deployed more than $2 billion in private equity investments in the past year alone, in addition to a recent $600 million financing of Manipal Group. This also builds on KKR's strong healthcare track record, including a fivefold return in Max Healthcare in 2022 that had also marked the largest block deal by a private equity firm in India, and recent investments in healthcare, including Healthcare Global Enterprises, BMH (Baby Memorial Hospital), Healthium and Chemicals said it had built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. 'As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets,' said Nikhil Chopra, chief executive officer and whole time director of JB Chemicals.
Time of India
an hour ago
- Time of India
Torrent Pharma to Acquire JB Chemicals at ₹25k cr Valuation
Ahmedabad-based drugmaker Torrent Pharma has agreed to buy a controlling stake in JB Chemicals from global private equity firm KKR at an equity valuation of ₹25,689 crore ($3 billion). The deal, which will see a merger of the two entities, is among the biggest in the Indian pharmaceutical sector and brings to an end year-long negotiations. They had come close to a deal last year but couldn't agree on valuation at the time. With the acquisition of JB Chemicals, Torrent will move up to fifth rank by market share in the $26 billion Indian pharmaceutical market ahead of Alkem and Intas Pharma. ET had on June 29 been the first to report on the merger details. The deal was announced following a marathon meeting of Torrent Pharma's board of directors on Sunday. That's against the stock's Friday close of ₹1,792. Torrent will also acquire up to 2.8% equity from certain employees of JB Chemicals at the Rs 1,600 apiece. The second part of the deal will follow a merger between Torrent and JB Chemicals through a scheme of arrangement. As per the approval by the two boards, upon the merger, every shareholder holding 100 shares in JB Chemicals will get 51 shares of Torrent. KKR had been the first to seek a restart of negotiations, according to the people cited above. Even at the discounted price, it will end with a fivefold return on what it paid to acquire JB Chemicals in 2020. Torrent Pharma posted FY25 revenue of ₹ 11,500 crore, of which the Indian market accounted for Rs 6,393 crore. JB Chemicals recorded total FY25 sales of Rs 3,918 crore, of which the Indian market accounted for Rs 2,269 crore, growing at 20% over the previous year. Over the last decade, Torrent has grown inorganically with a string of deals that included skincare drugs maker Curatio in 2022 and more recently a range of anti-diabetes drugs from Boehringer Ingelheim. A press statement from Torrent Pharma said the transaction marks a significant step in its ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO (contract development and manufacturing) capabilities. The deal is a strong fit for Torrent and complements its India presence, helping it move into the promising field of contract manufacturing besides allowing for market synergy, an analyst said. 'Torrent has a proven record of making deals work successfully,' the person added. The company will get access to leading brands in the chronic segment and entry into untapped therapeutic areas such as ophthalmology. Torrent said it will derive operational synergies across multiple business functions. 'We are pleased to have on board the JB Chemicals heritage and build on the platform for the future,' said Torrent Pharma executive chairman Samir Mehta. 'Torrent's deep India presence and JB Chemicals' fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability.' For KKR, this follows strong investment activity in India, where the buyout group has deployed more than $2 billion in private equity investments in the past year alone, in addition to a recent $600 million financing of Manipal Group. This also builds on KKR's strong healthcare track record, including a fivefold return in Max Healthcare in 2022 that had also marked the largest block deal by a private equity firm in India, and recent investments in healthcare, including Healthcare Global Enterprises, BMH (Baby Memorial Hospital), Healthium and Infinx. JB Chemicals said it had built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. 'As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets,' said Nikhil Chopra, chief executive officer and whole time director of JB Chemicals.
